PRE-CLINICAL EVALUATION OF THE LSD1 INHIBITOR HCI-2509: DEFINING THE BIOMARKERS OF SENSITIVITY AND THE MECHANISMS OF RESISTANCE

Abstract

Despite aggressive multi-modal treatment strategies, limited progress in the treatment of Ewing sarcoma (paediatric bone malignancy), has been achieved over the past 30 years. As such, the advent of novel and targeted therapeutics with favourable efficacy/toxicity profiles are eagerly awaited. This proposal will investigate the therapeutic utility of LSD1 inhibition as a treatment for Ewing sarcoma and the underlying mechanisms of sensitivity/resistance to this unique agent.

Related publications (1)

Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma.

Davis T Weaver, Kathleen I Pishas, Drew Williamson, Jessica Scarborough, Stephen L Lessnick, Andrew Dhawan, Jacob G Scott

2021-10-01

MicroRNA (miRNA)-based therapies are an emerging class of targeted therapeutics with many potential applications. Ewing Sarcoma pa..